Identification of Jun loss that promotes resistance to HDAC inhibitor Entinostat through Myc signaling in Luminal breast cancer [CGH]

ABSTRACT: The histone deacetylase inhibitor Entinostat is in phase III trials for patients with metastatic estrogen receptor-positive breast cancer. Predictors of sensitivity and resistance, however, remain unknown.

ORGANISM(S): Mus musculus

PROVIDER: GSE118743 | GEO | 2018/12/10

REPOSITORIES: GEO